WCM
CTMX icon

Weld Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Weld Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-84,445
Closed -$702K – 487
2019
Q4 		$702K Sell
84,445
-1,918
-2% -$12.9K 0.14% 258
2019
Q3 		$637K Buy
86,363
+70,880
+458% +$699K 0.12% 296
2019
Q2 		$174K Buy
+15,483
New +$162K 0.03% 663
2019
Q1 		– Sell
-29,411
Closed -$444K – 693
2018
Q4 		$444K Buy
+29,411
New +$436K 0.1% 388

Other funds holding CTMX

Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Weld Capital Management's CTMX Position: Q1 2020 in Review

Weld Capital Management sold out of CytomX Therapeutics (CTMX) in Q1 2020, closing a stake of 84,445 shares — an estimated $702K sold.

Weld Capital Management first reported a position in CTMX in Q4 2018 and held it in 4 quarters. The position peaked at $702K in Q4 2019. 117 funds tracked by Wall St. Rank hold CTMX as of Q1 2020.

  • Weld Capital Management reported no remaining CytomX Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Weld Capital Management sold 84,445 CytomX Therapeutics shares in Q1 2020, an estimated $702K.
  • Weld Capital Management first reported a position in CytomX Therapeutics in Q4 2018 and held it in 4 quarters.
  • Weld Capital Management's CytomX Therapeutics position peaked at $702K in Q4 2019.
  • 117 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2020.

Based on Weld Capital Management's 13F filing for Q1 2020, filed 15 May 2020.